Acadia pharmaceuticals announces plan for a resubmission of its supplemental new drug application to u.s. fda for nuplazid® (pimavanserin)

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) announced today that it plans to resubmit its supplemental new drug application (snda) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on alzheimer's disease psychosis (adp). resubmission of the snda to the u.s. food and drug administration (fda) is planned for the first quarter of 2022. “following our recent meetings with the fda, we plan to resubmit our snda for pimavanse
ACAD Ratings Summary
ACAD Quant Ranking